

# Reduced FEV<sub>1</sub>/FVC and FEV<sub>1</sub> in the Normal Range as a Physiological Variant

Luciana dos Santos Andreato, Maria Raquel Soares, and Carlos AC Pereira

**BACKGROUND:** Healthy individuals without respiratory symptoms can sometimes present with low FEV<sub>1</sub>/FVC. The objective of this study was to characterize and compare subjects without symptoms and with reduced FEV<sub>1</sub>/FVC but normal FEV<sub>1</sub> with subjects with mild obstructive lung disease. **METHODS:** Fifty healthy subjects with FEV<sub>1</sub>/FVC below the fifth percentile of reference values (normal variants) were compared with 52 subjects with asthma and 48 subjects with COPD who had similar FEV<sub>1</sub>/FVC. **RESULTS:** Subjects without symptoms were more likely to be male, younger, and taller, and to have higher FVC%, FEV<sub>1</sub>%, mid expiratory flow, and terminal flow than subjects with obstructive disease. A receiver operating characteristic curve analysis determined that the best separation between the groups was provided by age < 55 y, height ≥ 167 cm, and FVC > 105%. A logistic regression analysis confirmed that male sex, age, FVC%, and FEF<sub>75</sub> (Forced expiratory flow in 75% of forced vital capacity) were significant factors for discriminating subjects without symptoms from those with obstructive lung disease. **CONCLUSIONS:** A reduced FEV<sub>1</sub>/FVC may be a normal finding in younger-to-middle age male subjects with an FVC% value above the mean predicted value, especially when terminal flow is within the normal range. *Key words:* airway obstruction; asthma; chronic obstructive pulmonary disease; expiratory flow; lung function; lung functions testing; spirometry. [Respir Care 2019;64(5):570–575. © 2019 Daedalus Enterprises]

## Introduction

The diagnosis of obstructive lung disease can be made based on an FEV<sub>1</sub>/FVC below the fifth percentile of the predicted value,<sup>1</sup> and the diagnosis is reinforced by observed reductions in both FEV<sub>1</sub> and the FEV<sub>1</sub>/FVC. Physicians must be cautious when interpreting obstructive dysfunction from an FEV<sub>1</sub>/FVC below the lower limit of normal when FEV<sub>1</sub> and FVC are both higher than predicted values because this pattern is sometimes seen in healthy subjects.<sup>2</sup>

Smokers ages ≥ 40 y with a history of ≥20 pack-years of smoking have a higher risk for COPD. In these patients, a reduced FEV<sub>1</sub>/FVC has a high predictive value for diagnosis.<sup>3,4</sup> In healthy individuals without respiratory symptoms, a finding of a low FEV<sub>1</sub>/FVC with normal FEV<sub>1</sub> has been posited as a physiological variant of normal.<sup>5</sup>

In adults, the FEV<sub>1</sub>/FVC decreases with increased stature in both sexes.<sup>6</sup> In males with a tall stature, FEV<sub>1</sub>/FVC can be lower than expected.<sup>7</sup> Muscular force is greater in younger males with a taller stature and higher FVC values, which potentially cause decreased FEV<sub>1</sub> as a result of inverse effort dependence.<sup>8</sup> Mid and terminal expiratory flows are less effort dependent than FEV<sub>1</sub> and FVC, and are reduced in the early stages of diffuse obstructive diseases, such that they may be helpful for differentiating normal variants from patients with spirometric obstructive defects. The aim of this study was to identify factors that separate healthy subjects with reduced FEV<sub>1</sub>/FVC from subjects with mild obstructive lung disease.

## Methods

This was a prospective observational study of 150 subjects who visited 1 of 3 pulmonary function laboratories at

---

Ms dos Santos Andreato and Dr Pereira are affiliated with the Postgraduate Program in Internal Medicine, Civil Servant State Public Hospital of São Paulo, São Paulo, Brazil. Drs Soares and Pereira are affiliated with the Lung Function Laboratory, Brazil Diagnostic Center, São Paulo, Brazil.

The work was performed at the Brazil Diagnostic Center, São Paulo, Brazil.

The authors have disclosed no conflicts of interest.

Correspondence: Luciana dos Santos Andreato MB, 62 Santo Afonso St, Sete Lagoas, MG 35701-135 Brazil. E-mail: luluandreato@gmail.com.

DOI: 10.4187/respcare.06131

2 centers in São Paulo, Brazil. Spirometric testing was performed as part of an annual physician visit or a lung function assessment of several employers. The study was approved by the ethics committees of both participating centers. All the subjects completed an epidemiologic respiratory questionnaire, which was previously translated and validated in Brazil.<sup>9</sup> Spirometric tests were administered by certified technicians in accordance with the Brazilian Thoracic Society criteria.<sup>4</sup> Based on this guideline, the highest value of FEV<sub>1</sub> was selected from the 3 best curves, with peak expiratory values > 90% of the highest value. All the subjects were white and had age and height in the range of values used for the derivation of the reference values.<sup>6</sup>

All the subjects had a mildly decreased FEV<sub>1</sub>/FVC (below the fifth percentile of the predicted value, but >80% of the predicted value) and FEV<sub>1</sub> and FVC values within the normal range. The subjects were classified into 3 groups after review of the questionnaire responses: (1) normal variant, characterized by healthy non-smokers without present or past respiratory or cardiovascular disease, or any condition that could result in abnormal lung function; (2) asthma–non-smokers, with a current or past physician diagnosis of asthma with compatible symptoms as indicated by the questionnaire ( $\geq 2$  attacks of wheezing relieved by a bronchodilator); and (3) COPD-smokers, characterized by a physician diagnosis of COPD, a smoking history of >20 pack-years, and compatible symptoms as indicated by the questionnaire (the presence of chronic cough and/or dyspnea).

The sample size was estimated by using the variation in FVC values from the first 20 subjects included in each group because didn't have any previous studies to analyse the same data of this study. The analysis indicated that 40 subjects per group were sufficient to allow separation with  $\alpha < 0.05$  and  $\beta > 0.8$ . Normality of the data were evaluated by using the Kolmogorov-Smirnov test. Age, stature, and functional variables were adjusted to normal curves. Variables were compared among the 3 groups by using an analysis of variance and Tukey post hoc tests. Chi-square and Fisher exact tests were used to analyze categorical data.

A second analysis was performed in which subjects with asthma and COPD were compared with normal variant subjects. Age, height, FVC, and forced expiratory flows cutoff points for separating these 2 groups (one group - subjects with asthma and COPD and the other with normal variant) were calculated by using receiver operating characteristic curves. Finally, a logistic regression was performed for select variables to test the ability to discriminate the normal variant group from the obstructive defect group (both asthma group and COPD group). Data were expressed as mean  $\pm$  SD. All analyses were performed by using IBM SPSS statistics pack-

## QUICK LOOK

### Current knowledge

The diagnosis of obstructive lung disease is based on a reduced FEV<sub>1</sub>/FVC. The diagnosis of an obstructive lung defect is usually correct when FEV<sub>1</sub> and FEV<sub>1</sub>/FVC are both reduced. One should be cautious in characterizing obstructive dysfunction when the FEV<sub>1</sub>/FVC is below the lower limit of normal but FEV<sub>1</sub> and FVC are in the normal range because this pattern is sometimes seen in healthy individuals.

### What this paper contributes to our knowledge

This study showed that, in comparison with the subjects with asthma and COPD with mild air-flow obstruction, reduced FEV<sub>1</sub>/FVC should be considered as a normal variant in young and non-elderly adults males who are asymptomatic and with FVC above mean predicted values and terminal flows within the normal range.

age version 19.0. A *P* value of < .05 was considered to be statistically significant.

## Results

Of 150 subjects evaluated, 95 were male and 55 were female. Fifty were classified into the normal variant group, 48 into the asthma group, and 52 into the COPD group. Anthropometric and spirometric data for the 3 groups are summarized in Table 1. In terms of absolute values, FEV<sub>1</sub>/FVC values were lowest in the COPD group; however, when the values were calculated as percentages of predicted values, there were no notable differences among the 3 groups. There was a larger proportion of male subjects in the normal variant group (86%) compared with the asthma (48%) and COPD groups (56%) ( $\chi^2 = 17.26$ ,  $P < .001$ ).

The subjects in the normal variant and asthma groups were similar in terms of age but were younger than those in the COPD group. A receiver operating characteristic curve analysis revealed that age < 55 y was the best cutoff for separating the normal variant group from the asthma and COPD cohorts (area under the curve, 0.70 [95% CI 0.62–0.78]). In the normal variant group, 88% of the subjects were < 55 y of age compared with 52% of subjects in the obstructive defect group (both asthma group and COPD group) ( $\chi^2 = 18.75$ ,  $P < .001$ ). Mean height was higher in the normal variant group compared with the asthma and COPD groups. A receiver operating characteristic curve analysis revealed that height  $\geq 167$  cm was the best cutoff for separating the normal variant group from the asthma and COPD groups (area under the curve,

PHYSIOLOGICAL VARIANTS OF FEV<sub>1</sub>/FVC AND FEV<sub>1</sub>

Table 1. Demographic and Functional Data in Normal Variant Group and Subjects With Asthma and COPD

Variable	Normal Variant Group (n = 50)	Asthma Group (n = 48)	COPD Group (n = 52)	P
Age, mean ± SD y	42 ± 10	44 ± 15	61 ± 12	<.001
Male/female, n	43/7	23/25	29/23	<.001
Height, mean ± SD cm	173 ± 9	166 ± 9	165 ± 10	<.001*
Body mass index, mean ± SD kg/m <sup>2</sup>	27.0 ± 4.0	27.6 ± 4.4	26.1 ± 3.8	.15
FVC% predicted, mean ± SD	110 ± 10	104 ± 10	102 ± 10	.001*
FEV <sub>1</sub> % predicted, mean ± SD	95 ± 8	90 ± 8	89 ± 9	<.001*
FEV <sub>1</sub> /FVC, mean ± SD	0.70 ± 0.02	0.71 ± 0.02	0.68 ± 0.02	<.001*
FEV <sub>1</sub> /FVC, mean ± SD %	86 ± 2	87 ± 2	86 ± 2	.56
FEF <sub>max</sub> , mean ± SD %	84 ± 11	80 ± 12	79 ± 15	.19
FEF <sub>50</sub> , mean ± SD %	67 ± 10	62 ± 8	60 ± 10	<.001*
FEF <sub>50</sub> reduced, %	18	35	40	.04†
FEF <sub>25-75%</sub> , mean ± SD, %	68 ± 10	61 ± 9	57 ± 9	<.001*
FEF <sub>25-75</sub> reduced, %	16	38	63	<.01
FEF <sub>75</sub> , mean ± SD, %	71 ± 15	61 ± 12	56 ± 11	<.001*
FEF <sub>75</sub> reduced, %	22	42	58	.001
FEF <sub>75-85</sub> , mean ± SD, %	72 ± 20	61 ± 14	58 ± 12	<.001*
FEF <sub>75-85</sub> reduced, %	18	38	40	.03

\* Tukey test: normal variant vs asthma and COPD.

†  $\chi^2$  test: normal variant vs asthma and COPD.

FEF<sub>max</sub> = Peak expiratory flow

FEF<sub>50</sub> = Forced expiratory flow 50% of CVF

FEF<sub>25-75%</sub> = forced expiratory flow during the middle half of the FVC maneuver

FEF<sub>75</sub> = Forced expiratory flow 75% of CVF

FEF<sub>75-85</sub> = Forced expiratory flow Between 75–85% of CVF

0.72 [95% CI 0.63–0.80]). In the normal variant group, 80% of subjects had heights  $\geq$  167 cm compared with 46% of subjects in the obstructive defect group (both asthma group and COPD group) ( $\chi^2 = 15.75, P < .001$ ).

FVC and FEV<sub>1</sub> values were higher in the normal variant group than in the other groups (Table 1). Tukey post hoc tests revealed that this difference was significant between the normal variant and asthma groups and between the normal variant and COPD groups. A receiver operating characteristic curve analysis revealed that FVC > 105% of predicted was the best cutoff for separating the normal variant group from the asthma and COPD groups (area under the curve, 0.70 [95% CI 0.61–0.79]). In the normal variant group, 68% of subjects had FVC > 105% of predicted compared with 35% of the subjects in the obstructive defect group (both asthma group and COPD group) ( $\chi^2 = 14.61, P < .001$ ).

Flows at mid and low lung volumes were higher in the normal variant group than in the other groups (Table 1). A receiver operating characteristic curve analysis revealed that FEF<sub>25-75%</sub> and FEF<sub>75</sub> values had the largest areas under the curve for separating the normal variant group from the asthma and COPD groups (Fig. 1). In the normal variant group, 84% of subjects had an FEF<sub>25-75%</sub> value in the normal range compared with 49% of the subjects in the obstructive defect group ( $\chi^2 = 17.11, P < .001$ ). Similarly, 78% of the subjects in the normal variant group had




Fig. 1. Receiver operating characteristic curves for mid and terminal flows in normal variant cases and subjects with air-flow obstruction.

an FEF<sub>75</sub> value in the normal range compared with 50% of the subjects in the obstructive defect group ( $\chi^2 = 10.83, P < .001$ ).

A logistic regression analysis confirmed that sex, age, FVC% and FEF<sub>75</sub> were significant factors for separating the normal variant group from the obstructive defect group (Table 2). Stature and FEF<sub>25-75%</sub> were not signif-

Table 2. Adjusted Logistic Regression for Determination of Probability of Normal Variant in Comparison With Subjects With Mild Obstructive Disease (Asthma and COPD)

Variable	Odds Ratio (95% CI)	P
Males	10.57 (3.50–31.00)	<.001
Age < 55 y	5.67 (1.91–16.84)	.002
FVC > 105% predicted	4.08 (1.66–10.04)	.002
FEF <sub>75</sub> reduced	2.79 (1.07–7.30)	.036

Adjusted for height and FEF<sub>25-75%</sub>.  
FEF<sub>75</sub> = Forced expiratory flow 75% of CVF

icant in this analysis (data not shown). When only males were compared between normal variants (*n* = 43) and subjects with asthma and COPD (*n* = 52), higher values were still found in normal variants (FVC = 109.9 ± 9.6% vs to 102.0 ± 8.3% and FEF<sub>75</sub> 70.7 ± 16.0% vs 57.8 ± 10.5% of predicted values, *P* < .01 for both comparisons).

**Discussion**

The present study found that, compared with the subjects with asthma or COPD, normal variant individuals (characterized by a low FEV<sub>1</sub>/FVC and FEV<sub>1</sub> in the normal range) were more likely to be male, younger, and have higher FVC and FEF<sub>75</sub> values in the normal range. Only 2 previous studies evaluated subjects without symptoms and with low FEV<sub>1</sub>/FVC, and compared them with a control group or subjects with obstructive disease.<sup>5,10</sup> In the first published study, healthy males who showed reduced FEV<sub>1</sub>/VC (FEV<sub>1</sub>/vital capacity) were compared with healthy subjects with FEV<sub>1</sub>/VC within the normal range and with similar age.<sup>10</sup> Spirometric response to bronchodilators, lung volumes, and bronchial provocation tests were similar between the 2 groups.<sup>10</sup> The second study performed a careful analysis of respiratory symptoms combined with sensitivity tests for detecting airway obstruction in an attempt to separate healthy subjects (*n* = 7) with low FEV<sub>1</sub>/FVC from subjects with respiratory disease (*n* = 33).<sup>5</sup> The investigators concluded that routine lung function tests were of little use for separating patients with physiological variants from those with respiratory disease; however, data for mid and terminal flows were not shown.<sup>5</sup> In contrast, most cases with respiratory symptoms show additional abnormalities on sensitive tests of airway mechanics.

There are 2 plausible reasons for the observation of low FEV<sub>1</sub>/FVC in healthy subjects: dysanapsis and inverse effort dependence on expiratory flow. The term dysanapsis has been used to reflect physiological variation in the geometry of the tracheobronchial tree and lung parenchyma

due to different (unequal) patterns of growth. Mead<sup>11</sup> examined the association between airway size (estimated by using maximal expiratory flow/static recoil pressure at 50% VC) and lung size (estimated by using VC) in adult men and women, and found that airway diameter was, on average, 17% larger in healthy adult men than in women. Additional support for the relevance of dysanapsis to the observation of low FEV<sub>1</sub>/FVC in healthy subjects comes from studies that estimated the acoustic reflectance of the tracheal area in healthy young men and healthy adult women. In a subset of subjects matched for total lung capacity, Martin et al<sup>12</sup> found that the tracheal cross-sectional area was 29% smaller in women than in men. More recently, Sheel et al<sup>13</sup> used computed tomography to show that the largest conducting air ways in females are significantly smaller than those in males, even after controlling for lung size. In the present study, the normal variant group was 86% male, which indicated that dysanapsis was not the cause of low FEV<sub>1</sub>/FVC in the whole sample.

Several studies showed that submaximal expiratory effort can increase expiratory flows.<sup>14,15</sup> In one critical study, Krowka et al<sup>8</sup> evaluated the difference between the highest FEV<sub>1</sub> observed in expiratory maneuvers with variable effort and FEV<sub>1</sub> from the maneuver with the greatest peak expiratory flow, and found that the difference for FEV<sub>1</sub> was always > 0 with lower degrees of effort; the mean difference in all the sessions was 110 mL.<sup>8</sup> When poorly reproducible maneuvers were excluded from the analysis, this difference decreased to 80 mL but remained significant (*P* < .05).<sup>8</sup> The investigators concluded that, during standard spirometry, FEV<sub>1</sub> is inversely dependent on effort due to the effect of thoracic gas compression on lung volume, and as a result, the investigators recommended the exclusion of FEV<sub>1</sub> values from spirometry maneuvers performed with submaximal effort as indicated by a decrease in peak expiratory flow.<sup>8</sup> In the present study, FEV<sub>1</sub> values were selected from maneuvers with a peak expiratory flow of >90% of the highest value.<sup>4</sup> It is notable that the influence of inverse effort dependence on FEV<sub>1</sub> was greater in patients with obstructive lung disease.

The compressed volume of intrathoracic gas is influenced by alveolar pressure and lung volume, which, in turn, are influenced by a combination and interaction of length-tension and force-velocity relationships in respiratory muscles, lung elastic recoil pressure, lung volume, and airway resistance.<sup>8</sup> Our observation that physiological variants were more likely to be young males with high FVC values can be explained by several possible mechanisms. First, young male subjects generate greater expiratory efforts during forced expiratory maneuvers. A higher FVC indicates an advantage for the expiratory muscles, that is, greater length results in greater force. A high FVC could also be the result of greater force exerted by the inspiratory muscles. In our logistic regression analysis,

FVC but not stature remained significant as a factor that discriminated the normal variant group from the obstructive defect group. This finding indicated that muscle force was the most relevant finding (greater lung gas compression occurred as a result of greater muscular effort), even in male subjects with shorter statures.

Lastly, it is well known that flows at low lung volume are less influenced by respiratory effort than flows at higher lung volumes<sup>16</sup>; therefore, it was expected that flows at low lung volumes would be better preserved (ie, closer to normal) in the normal variant group. Indeed, we found that all mid and terminal flows were preserved when expressed as percentages of the predicted values in the normal variant group compared with the asthma and COPD groups. Maintenance of flows in lower lung volumes can also be explained by higher values of FVC because these flows are dependent on lung volume. In our study, flows in lower volumes were more preserved in comparison with FEV<sub>1</sub>/FVC but were not always reduced in cases generally with asthma/COPD. The inclusion criterion was reduced FEV<sub>1</sub>/FVC in all the subjects, although to a mild degree. We commonly observed that isolated reduction in terminal expiratory flows can be the only abnormality indicative of air-flow obstruction, usually in patients with FVC values in the lower range of reference values.

The present study had several limitations. We did not perform detailed tests of lung function, such as measurements of slow vital capacity, diffusing capacity of the lung for carbon monoxide, response to bronchodilator, respiratory pressures, and bronchoprovocation tests. However, 2 studies did not show bronchial hyper-responsiveness in normal variant subjects, which indicated that these tests would have yielded normal results.<sup>5,10</sup> Healthy subjects were not re-evaluated after bronchodilator use due to the need for quick consecutive testing in checkup evaluations. Unfortunately, the total number of non-smokers who were asymptomatic and who received routine spirometry was not designed to calculate the prevalence of normal variants.

Muller<sup>7</sup> observed that, in community surveys, many taller subjects could have reduced FEV<sub>1</sub>/FVC with FEV<sub>1</sub> within the normal range. The investigator indicated that this could reflect inaccuracies in the regression equations used to predict normal values because relatively few subjects of such great height are included. In the present study, all the subjects had both age and height within the range of reference values. Reference values in Brazilian white male adults were derived from 270 subjects.<sup>6</sup> Of these, 165 were ages  $\leq 50$  y and, of these, the mean  $\pm$  SD was  $172.4 \pm 6.9$  cm. In 43 male subjects in the normal variant group in the present study, the mean  $\pm$  SD age was  $42.6 \pm 9.3$  y and mean  $\pm$  SD height was  $175.3 \pm 7.1$  cm ( $t = 2.44$ ,  $P = .02$ ). When stature was entered in logistic regression, it became nonsignificant, with FVC% being more relevant.

In the subjects in the normal variant group in the present study, the lower limit for FEV<sub>1</sub>/FVC by using Brazilian reference values would be, for a male with the same mean age and stature, 0.74, compared with 0.70 by both Hankinson and Global Lung Initiative (GLI) reference values.<sup>17,18</sup> Hankinson values to predict FEV<sub>1</sub>/FVC do not include stature. In GLI equations, there was a very small inverse correlation between stature and FEV<sub>1</sub>/FVC. In Brazilian equations, FEV<sub>1</sub>/FVC correlated inversely with stature. Compared with the Brazilian reference values, the GLI equations have lower limits for FEV<sub>1</sub>/FVC, decreasing its sensitivity for a diagnosis of air-flow obstruction.<sup>19,20</sup> Brazilian equations for spirometry were validated in a second study.<sup>21</sup> The diagnosis of asthma was obtained by questionnaire, with several subjects who reported past diagnoses of asthma, such as during childhood. It is noteworthy that air-flow obstruction and bronchial hyper-responsiveness can persist long after a clinical remission of asthma.<sup>17</sup> Also, the results of the present study should be tested in a validation sample.

## Conclusions

Reduced FEV<sub>1</sub>/FVC was not necessarily indicative of air-flow obstruction in otherwise healthy adults. The possibility of normal variant status should be considered in patients who are asymptomatic, especially in males  $< 55$  y of age with an FVC above mean values and FEF<sub>75</sub> values in the normal range.

## REFERENCES

1. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. *Eur Respir J* 2005;26(5):948-968.
2. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. *Am Rev Respir Dis* 1991; 144(5):1202-1218.
3. Ohar JA, Sadeghnejad A, Meyers DA, Donohue JF, Bleecker ER. Do symptoms predict COPD in smokers? *Chest* 2010;137(6):1345-1353.
4. Pereira CAC. Spirometry. In: Pereira CAC, Neder JA. Guidelines for Lung Function Tests. *J Bras Pneumol* 2002;28(Suppl 3):1-82.
5. Barisione G, Crimi E, Bartolini S, Saporiti R, Copello F, Pellegrino R, Brusasco V. How to interpret reduced forced expiratory volume in 1 s (FEV<sub>1</sub>)/vital capacity ratio with normal FEV<sub>1</sub>. *Eur Respir J* 2009;33(6):1396-1402.
6. Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. *J Bras Pneumol* 2007;33(4): 397-406.
7. Muller A. Spirometry and maximal expiratory flow-volume curves. In Muller A. (Ed): *Pulmonary function tests in clinical and occupational disease*. Orlando, FL: Grune & Stratton; 1986:15-52.
8. Krowka MJ, Enright PL, Rodarte JR, Hyatt RE. Effect of effort on measurement of forced expiratory volume in one second. *Am Rev Respir Dis* 1987;136(4):829-833.
9. Aguiar VAN, Beppu OS, Romaldini H, Ratto OR, Nakatani J. Validity of a respiratory modified questionnaire (ATS-DLS-78) as a tool of an epidemiologic study in Brazil. *J Pneumol* 1988;14(3):111-116.

10. Kivity S, Solomon A, Schwarz Y, Trajber I, Topilsky M. Evaluation of asymptomatic subjects with low forced expiratory ratios (FEV<sub>1</sub>/VC). *Thorax* 1994;49(6):554-556.
11. Mead J. Dysanapsis in normal lungs assessed by the relationship between maximal flow, static recoil, and vital capacity. *Am Rev Respir Dis* 1980;121(2):339-342.
12. Martin TR, Castile RG, Fredberg JJ, Wohl ME, Mead J. Airway size is related to sex but not lung size in normal adults. *J Appl Physiol* 1987;63(5):2042-2047.
13. Sheel AW, Guenette JA, Yuan R, Holy L, Mayo JR, McWilliams AM, et al. Evidence for dysanapsis using computed tomographic imaging of the airways in older ex-smokers. *J Appl Physiol* 2009;107(5):1622-1628.
14. Ingram RH Jr, Schilder DP. Effect of gas compression on pulmonary pressure, flow, and volume relationship. *J Appl Physiol* 1966;21(6):1821-1826.
15. Sharafkhaneh A, Babb TG, Officer TM, Hanania NA, Sharafkhaneh H, Boriek AM. The confounding effects of thoracic gas compression on measurement of acute bronchodilator response. *Am J Respir Crit Care Med* 2007;175(4):330-335.
16. Mead J, Turner JM, Macklem PT, Little JB. Significance of the relationship between lung recoil and maximum expiratory flow. *J Appl Physiol* 1967;22(1):95-108.
17. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med* 1999;159(1):179-187.
18. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012;40(6):1324-1343.
19. Linares-Perdomo O, Hegewald M, Collingridge DS, Blagev D, Jensen RL, Hankinson J, Morris AH. Comparison of NHANES III and ERS/GLI 12 for airway obstruction classification and severity. *Eur Respir J* 2016;48(1):133-141.
20. Pereira CA, Duarte AA, Gimenez A, Soares MR. Comparison between reference values for FVC, FEV<sub>1</sub>, and FEV<sub>1</sub>/FVC ratio in White adults in Brazil and those suggested by the Global Lung Function Initiative 2012. *J Bras Pneumol* 2014;40(4):397-402.
21. Duarte AA, Pereira CA, Rodrigues SC. Validation of new Brazilian predicted values for forced spirometry in Caucasians and comparison with predicted values obtained using other reference equations. *J Bras Pneumol* 2007;33(5):527-535.
22. Boulet LP, Turcotte H, Brochu A. Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. *Chest* 1994;105(4):1024-1031.